跳至主導覽
跳至搜尋
跳過主要內容
國立陽明交通大學研發優勢分析平台 首頁
English
中文
首頁
人員
單位
研究成果
計畫
獎項
活動
貴重儀器
影響
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
許 中華
教授
傳統醫藥研究所
電話
(02)2388-7088 ext 3100
電子郵件
owlherbs
yahoo.com
tw
h-index
h10-index
h5-index
1968
引文
22
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
979
引文
16
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
269
引文
11
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2005
2024
每年研究成果
概覽
指紋
網路
研究成果
(97)
類似的個人檔案
(6)
指紋
查看啟用 Chung-Hua Hsu 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Keyphrases
Traditional Chinese Medicine
81%
Quality of Life
72%
Acupuncture
59%
Taiwan
59%
Obese Women
52%
Kuan-Sin-Yin
45%
Body Mass Index
43%
Green Tea Extract
34%
Randomized Controlled Trial
34%
Breast Cancer Patients
33%
Insulin Resistance
29%
Type 2 Diabetes Mellitus (T2DM)
29%
Waist Circumference
29%
Electroacupuncture
27%
In Cancer
26%
Placebo-controlled Clinical Trial
24%
Obesity
23%
Meta-analysis
22%
Chinese Medicine
22%
Hormone Peptide
22%
Cancer Patients
20%
Chemotherapy
20%
Methadone
19%
Traditional Chinese Medicine Syndrome
19%
Qi Deficiency
18%
Liver Function
17%
Randomized Double-blind
17%
NLRP3 Inflammasome
17%
Cancer-related Fatigue
17%
Buprenorphine-naloxone
17%
Laser Doppler
17%
Aqueous Humor
17%
Systematic Meta-analysis
17%
Chinese Herbal Formula
17%
Randomized Placebo-controlled Trial
15%
Breast Cancer
15%
Type 2 Diabetic
14%
Leptin Levels
13%
Poor Quality of Life
13%
Pulse Waveform
13%
Exosomes
13%
Therapeutic Effect
13%
Clinical Observation
13%
COVID-19
13%
Home Health Care
13%
Taipei
12%
Type 2 Diabetic Patients
12%
Doppler Indices
12%
Randomized Double-blind Controlled Clinical Trial
12%
Heart Rate Variability
11%
Medicine and Dentistry
Traditional Chinese Medicine
100%
Auriculotherapy
64%
Quality of Life
60%
Breast Cancer
52%
Symptom
36%
Malignant Neoplasm
36%
Body Mass Index
28%
Randomized Controlled Trial
27%
Meta-Analysis
22%
Placebo
21%
Disease
19%
Chinese Herbal Medicine
17%
Systematic Review
17%
Acupuncture Point
17%
Cancer-Related Fatigue
17%
Maturity Onset Diabetes of the Young
17%
Pulse Rate
17%
Controlled Clinical Trial
17%
Acneiform Eruption
17%
Drug Therapy
15%
Qi Deficiency
15%
Methadone
14%
Home Health Care
13%
Insulin Resistance
13%
Auricular Acupuncture
13%
Herbal Medicine
12%
Blood Pressure
12%
Electroacupuncture
12%
Heart Rate Variability
11%
Adverse Event
11%
Cohort Analysis
11%
Buprenorphine Plus Naloxone
11%
Severe Acute Respiratory Syndrome
11%
Patient with Hypertension
11%
Elderly Patient
11%
Group Therapy
9%
Peptide Hormone
9%
Medicine
9%
Pulse Wave Velocity
9%
Antihypertensive Agent
8%
Side Effect
8%
Therapy Effect
8%
Combination Therapy
8%
Skin Surface
8%
Laser Doppler Flowmetry
8%
Cancer Therapy
8%
Maintenance Therapy
7%
Methadone Treatment
7%
Odds Ratio
7%
Retrospective Study
7%
Pharmacology, Toxicology and Pharmaceutical Science
Traditional Chinese Medicine
89%
Placebo
56%
Controlled Clinical Trial
42%
Symptom
41%
Disease
35%
Auriculotherapy
34%
Breast Cancer
34%
Sinecatechins
34%
Malignant Neoplasm
23%
Infection
22%
Methadone
21%
Non Insulin Dependent Diabetes Mellitus
20%
Mouse
19%
Insulin Resistance
19%
Inflammation
17%
Syndrome
17%
SARS Coronavirus
17%
Peptide Hormone
14%
Inflammasome
11%
Agaricus subrufescens
11%
Agaricus blazei
11%
Electroacupuncture
11%
Cohort Study
11%
Buprenorphine Plus Naloxone
11%
Antiinflammatory Activity
11%
Side Effect
10%
Leptin
9%
Ghrelin
8%
Adiponectin
8%
Colon Cancer
8%
Randomized Controlled Trial
8%
Therapeutic Effect
8%
Tumor Necrosis Factor
8%
Adverse Event
8%
Opiate
7%
Coronavirinae
7%
Diabetes Mellitus
7%
Carcinogenesis
7%
High Density Lipoprotein Cholesterol
7%
Triacylglycerol
7%
Alanine Aminotransferase
7%
Cytokine
6%
Immunomodulation
6%
Bladder Cancer
6%
Combination Therapy
6%
Anti-Inflammatory Drug
6%
Metabolic Syndrome X
6%
Arthralgia
6%
Diamorphine
6%
Acupuncture Point
6%
